• Aucun résultat trouvé

[PDF] Top 20 Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes

Has 10000 "Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes" found on our website. Below are the top 20 most common "Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes".

Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes

Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes

... Chronic kidney disease is associated with homeostatic imbalances such as insulin resis- ...However, the underlying mechanisms leading to these imbalances and whether they promote ... Voir le document complet

17

Early reduction of circulating homocysteine levels in Goto-Kakizaki rat, a spontaneous nonobese model of type 2 diabetes

Early reduction of circulating homocysteine levels in Goto-Kakizaki rat, a spontaneous nonobese model of type 2 diabetes

... Abstract Diabetes mellitus is associated with increased risk for cardiovascular disorders, which are major causes of mortality in this ...independent risk factor for the ... Voir le document complet

22

Canagliflozin: A Review in Type 2 Diabetes.

Canagliflozin: A Review in Type 2 Diabetes.

... Introduction Type 2 diabetes (T2D) is a chronic progressive metabolic disease characterized by hyperglycaemia, due to insulin resistance/insufficient insulin ... Voir le document complet

20

Cardiovascular and sensory abnormalities in a rat model of insulin resistance : beneficial effect of an antioxidant and an angiotensin-1 converting enzyme inhibitor

Cardiovascular and sensory abnormalities in a rat model of insulin resistance : beneficial effect of an antioxidant and an angiotensin-1 converting enzyme inhibitor

... author and co-authors if applicable retain copyright ownership and moral rights in this ...Neither the whole thesis or dissertation, nor substantial extracts from it, may be printed or ... Voir le document complet

140

Pharmacological prevention of type 2 diabetes.

Pharmacological prevention of type 2 diabetes.

... The results suggest that 11 patients with IGT would need to be treated for ...event of development of ...reduced risk of developing T2DM irrespective of age, sex, ... Voir le document complet

46

DPP-4 inhibitors in the treatment of type 2 diabetes.

DPP-4 inhibitors in the treatment of type 2 diabetes.

... inhibitors and cardiovascular risk Numerous studies have evidenced a role for GLP-1 in the cardiovascular ...On the one hand, continuous IV administration of GLP-1 ... Voir le document complet

27

Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury

Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury

... become a cornerstone treatment in the primary and sec- ondary prevention of atherosclerotic cardiovascular disease ...4,5 Kidney diseases, notably acute kidney ... Voir le document complet

9

Glycemia, Insulin Resistance, Insulin Secretion, and Risk of Depressive Symptoms in Middle Age.: Glycemia, insulin secretion & depressive symptoms

Glycemia, Insulin Resistance, Insulin Secretion, and Risk of Depressive Symptoms in Middle Age.: Glycemia, insulin secretion & depressive symptoms

... significance. In contrast, women in the first quintile of HOMA2-%B ...levels of insulin secretion) showed significantly increased odds of developing DepS compared ... Voir le document complet

26

Risk factors of impaired fasting glucose and type 2 diabetes in Yaounde, Cameroon: a cross sectional study

Risk factors of impaired fasting glucose and type 2 diabetes in Yaounde, Cameroon: a cross sectional study

... causes of morbidity and mortality including cardiovascular dis- eases (CVD), retinopathies, nephropathies and neuropa- ...percent of people living with T2D die of cardiovascular ... Voir le document complet

11

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.

... renal disease (ESRD) requiring hemodialysis 152 ...studies in patients with T2DM to explore the relationship of exenatide clearance (CL/F) and CL CR ...RI and ESRD groups were ... Voir le document complet

48

A catalog of gene expression in the developing kidney.

A catalog of gene expression in the developing kidney.

... to the Editor 867 mesothelial cells,” but, to our knowledge, these authors never employed immunohistochemical analysis in any of their published papers on peritoneal biopsy ...guish the ... Voir le document complet

2

Supplementary material: Plasma Trimethylamine N-oxide and risk of cardiovascular events in patients with type 2 diabetes

Supplementary material: Plasma Trimethylamine N-oxide and risk of cardiovascular events in patients with type 2 diabetes

... is a multi-disciplinary open access archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or ...not. The documents may come from ... Voir le document complet

8

Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study

Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study

... Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an ... Voir le document complet

9

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.

... Received: 4 September 2009 / Accepted: 22 September 2009 # The Author(s) 2009. This article is published with open access at Springerlink.com Keywords Allocation bias . Causality . Ethics . Inclusion criteria . ... Voir le document complet

3

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

... for the management of T2DM. By inhibiting GLP-1 degradation and increasing circulating levels, thereby promoting insulin secretion and reducing glucagon secretion, both in ... Voir le document complet

15

Characterizing the modulation of mGluR5 in a 6-OHDA-induced rat model of Parkinson's disease

Characterizing the modulation of mGluR5 in a 6-OHDA-induced rat model of Parkinson's disease

... The right (with lesion) side of the brain showed enhanced mGluR5 binding characteristics, suggesting a complementary and compensatory role of metabotropic glutamate rece[r] ... Voir le document complet

27

Pioglitazone reduces insulin requirements and improves glycaemic control in insulin-treated patients with type 2 diabetes: results from PROactive

Pioglitazone reduces insulin requirements and improves glycaemic control in insulin-treated patients with type 2 diabetes: results from PROactive

... University of Liege, Belgium. Background and Aims: Type 2 diabetes is a progressive disease with associated insulin resistance and diminished ... Voir le document complet

2

en
                                                                    fr

en fr The role of LDLR and PCSK9 in type 2 diabetes Le rôle du récepteur aux LDL et de PCSK9 dans le diabète de type 2

... Maxwell and Breslow, 2004; Park et ...Horton a démontré que le plasma des souris transgéniques avait la capacité de réduire l'expression du LDLR chez les souris témoins parabiosées et d'augmenter leur ... Voir le document complet

270

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

... interactions. The mammalian mitochondrial respiratory‐chain complex 1 is a large L‐shaped membrane‐ bound redox enzyme (also known as NADH:ubiquinone oxidoreductase) consisting of 14 core subunits ... Voir le document complet

51

Increased risk of type 2 diabetes in antidepressant users: evidence from a 6-year longitudinal study in the E3N cohort

Increased risk of type 2 diabetes in antidepressant users: evidence from a 6-year longitudinal study in the E3N cohort

... Strengths of the present study include the fact that it comprised a large number of women with a 6-year follow-up, taking into account different pharmacological classes of ... Voir le document complet

24

Show all 10000 documents...